Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action

Khoury, Aleen; Deo, K.; Aldrich‐Wright, Janice R.

doi:10.1016/j.jinorgbio.2020.111070

Cited by 72 publications

(39 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] In view of this, platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin are used worldwide to treat patients. [4][5][6] However, adverse side effects and increased drug resistance results in lack of specicity towards cancer targets. 7 As a result, nanoformulations that involve inorganic platinum nanoparticles have not yet entered clinical studies so far.…”

Section: Introductionmentioning

confidence: 99%

A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Simultaneous modulation of additional biological targets, or synergistic/additive activity against the same target, can be beneficial for treating malignancies that develop resistance to a particular group of drugs. Cisplatin and platinum(II)-based analogs are approved for the treatment of many solid tumors [ 62 , 63 , 64 ]. Unfortunately, these DNA-damaging drugs exhibit severe toxicity due to a lack of selectivity.…”

Section: Hybrid Drugs As An Answer To the Anticancer Drug Resistance Problem?mentioning

confidence: 99%

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?

2021

View full text Add to dashboard Cite

Despite enormous progress in the treatment of many malignancies, the development of cancer resistance is still an important reason for cancer chemotherapy failure. Increasing knowledge of cancers’ molecular complexity and mechanisms of their resistance to anticancer drugs, as well as extensive clinical experience, indicate that an effective fight against cancer requires a multidimensional approach. Multi-target chemotherapy may be achieved using drugs combination, co-delivery of medicines, or designing hybrid drugs. Hybrid drugs simultaneously targeting many points of signaling networks and various structures within a cancer cell have been extensively explored in recent years. The single hybrid agent can modulate multiple targets involved in cancer cell proliferation, possesses a simpler pharmacokinetic profile to reduce the possibility of drug interactions occurrence, and facilitates the process of drug development. Moreover, a single medication is expected to enhance patient compliance due to a less complicated treatment regimen, as well as a diminished number of adverse reactions and toxicity in comparison to a combination of drugs. As a consequence, many efforts have been made to design hybrid molecules of different chemical structures and functions as a means to circumvent drug resistance. The enormous number of studies in this field encouraged us to review the available literature and present selected research results highlighting the possible role of hybrid drugs in overcoming cancer drug resistance.

show abstract

“…Alkylating agents (including nitrogen mustard, ethyleneimine, nitrosourea, methylxanthate, and epoxy compounds) can produce intra-chain or inter-chain cross links or transfer alkyl groups to guanine residues of DNA, leading to the formation of DNA base mispairs and preventing strand separation during DNA synthesis [47]. Although platinum drugs are also alkylating agents, they do not interact with biological macromolecules, but form a complex with the N7 position of guanine, thereby inhibiting DNA replication and transcription, and inducing apoptosis [48]. Topo inhibitors, which are divided into [49], irinotecan [50], belotecan [51] and camptothecin (CPT) [52]) and topoisomerase II inhibitors (e.g., etoposide, teniposide), can inhibit the activity of Topo involved in DNA replication and transcription, causing DNA singlestrand or double-strand breaks.…”

Section: The Action Mechanism Of the Commonly Used Chemotherapeutic Drugsmentioning

confidence: 99%

Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy

Sun

Jing

et al. 2021

Sci. China Mater.

View full text Add to dashboard Cite

Combination chemotherapy is widely exploited to overcome multidrug resistance (MDR) and enhance the therapeutic effect of anti-tumor agents clinically. The traditional combination regimens applied in clinical practice still suffer from various obstacles, such as inevitable side effects. Fortunately, the application of nanotechnology and the proposal of co-delivery systems make the combination therapy more effective. The occurrence, development, and metastasis of tumors are closely related to the cell cycle. The sensitivity of tumor cells to chemotherapeutic drugs can be improved with the cooperation of cell cycle regulators. In this review, the influence of the cell cycle on tumorigenesis and development is introduced briefly. The current strategies of combining chemotherapeutic drugs and cell cycle regulators through codelivery systems are discussed in detail. We also sketch the possibility of treating tumors mildly via artificially controlling the cell cycle and outline the challenges and perspectives about the improvement of co-delivery systems for cancer therapy.

show abstract

Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action

Cited by 72 publications

References 109 publications

A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?

Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy

Contact Info

Product

Resources

About